Syros Pharmaceuticals, Inc. - Common Stock (SYRS)
Frequently Asked Questions About Syros Pharmaceuticals, Inc. - Common Stock (SYRS)
Are there any clinical trials ongoing at Syros Pharmaceuticals?
Yes, Syros Pharmaceuticals often has multiple clinical trials ongoing to evaluate the safety and efficacy of its drug candidates. These trials are critical in progressing ahead toward regulatory approvals and using participants' results to inform future drug development strategies.
Has Syros Pharmaceuticals partnered with any other companies?
Yes, Syros Pharmaceuticals has formed various collaborations and partnerships with other companies and research institutions to enhance its research and development capabilities. These collaborations often focus on sharing knowledge, technologies, and resources to accelerate clinical advancements.
How can investors keep up with Syros Pharmaceuticals?
Investors can keep up with Syros Pharmaceuticals by following the company's official website, particularly the investor relations section, where they can find press releases, financial reports, and updates about ongoing clinical trials. Additionally, attending earnings conference calls and listening to industry news are recommended.
How does Syros Pharmaceuticals finance its operations?
Syros Pharmaceuticals finances its operations through a combination of private and public equity funding, collaborations, grants, and potential revenue from drug sales as their products progress through development and commercialization phases.
Is Syros Pharmaceuticals publicly traded?
Yes, Syros Pharmaceuticals is publicly traded and listed on the Nasdaq stock exchange under the ticker symbol SYRS. As a publicly traded company, it must adhere to regulatory requirements, including regular financial reporting and disclosures.
What are some key products in development at Syros?
Syros is focused on developing a pipeline of gene control therapies that include SY-1425, a treatment for patients with acute myeloid leukemia, and SY-5609, which is being investigated for use in solid tumors. These candidates aim to execute a precision medicine approach to improve patient outcomes.
What distinguishes Syros Pharmaceuticals from other biotech companies?
Syros Pharmaceuticals distinguishes itself through its unique focus on gene control mechanisms and its innovative drug discovery approach, which integrates genetics with therapeutics. This specialization enables the company to explore untapped opportunities in cancer treatment and precision medicine.
What does Syros Pharmaceuticals, Inc. do?
Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative gene control therapies to treat cancer and other diseases. The company leverages its expertise in gene regulation to identify and develop drug candidates aimed at addressing unmet medical needs via targeted approaches.
What is Syros Pharmaceuticals' approach to drug development?
Syros Pharmaceuticals employs a gene control platform that utilizes sophisticated technologies to understand gene regulation and its implications in diseases. This platform informs their drug discovery and development processes, allowing them to create targeted therapies with the potential for greater efficacy and fewer side effects.
What is Syros Pharmaceuticals’ vision for the future?
Syros Pharmaceuticals envisions a future where innovative gene control therapies revolutionize the treatment landscape for cancer and other diseases, leading to improved patient outcomes. The company aims to establish itself as a leader in precision medicine and continuously expand its portfolio.
What is the organizational structure of Syros Pharmaceuticals?
Syros Pharmaceuticals has a streamlined organizational structure that includes key functional areas such as research and development, clinical operations, regulatory affairs, and corporate management. This structure supports efficient decision-making and fosters collaboration across departments.
What is the significance of Syros' gene control platform?
Syros' gene control platform is significant as it enables the company to discover and develop novel drugs that target the underlying mechanisms of diseases at a genetic level. This approach differentiates Syros from traditional methods, offering hope for more effective treatments tailored to individual patient profiles.
What is the stock symbol for Syros Pharmaceuticals?
The stock symbol for Syros Pharmaceuticals is SYRS. The company is publicly traded on the Nasdaq stock exchange, which enables investors to buy and sell shares of the company.
What kind of corporate social responsibility initiatives does Syros participate in?
Syros Pharmaceuticals is committed to corporate social responsibility, upholding ethical practices and contributing positively to the community. The company often engages in initiatives that promote health education, support diversity in the workforce, and contribute to research that addresses global health challenges.
What recent developments has Syros announced?
Recent developments from Syros Pharmaceuticals, including updates on clinical trial results, new drug candidates entering different stages of development, or potential partnerships, can typically be found in their press releases or investor relations materials. The company regularly updates stakeholders about its strategic progress.
What types of diseases is Syros Pharmaceuticals focused on treating?
Syros Pharmaceuticals primarily focuses on treating various forms of cancer, including acute myeloid leukemia and solid tumors. The company also explores treatments for other diseases imbued with genetic components, underscoring its commitment to tackling unmet medical needs.
When was Syros Pharmaceuticals founded?
Syros Pharmaceuticals was founded in 2012. Since its inception, the company has been working on harnessing the potential of gene control to create effective treatments for various oncological and hematological conditions.
Where is Syros Pharmaceuticals located?
Syros Pharmaceuticals is headquartered in Cambridge, Massachusetts. This location places the company in a vibrant ecosystem of biotechnology and pharmaceutical research and development, bolstering its innovation potential.
Who are the key executives at Syros Pharmaceuticals?
The leadership team at Syros Pharmaceuticals includes President and CEO, who oversees the company’s strategic vision and day-to-day operations, along with a group of experienced executives in roles related to scientific research, finance, and business development.
What is the current price of Syros Pharmaceuticals, Inc. - Common Stock?
The current price of Syros Pharmaceuticals, Inc. - Common Stock is 0.1172
When was Syros Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Syros Pharmaceuticals, Inc. - Common Stock was at 4:00 pm EDT on March 19th, 2025
What is the market capitalization of Syros Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Syros Pharmaceuticals, Inc. - Common Stock is 2.41M
How many shares of Syros Pharmaceuticals, Inc. - Common Stock are outstanding?
Syros Pharmaceuticals, Inc. - Common Stock has 20.60M shares outstanding.